"AstraZeneca today announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician's choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations. Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy (capecitabine, vinorelbine or eribulin)."
http://www.investegate.co.uk/astrazenec ... 00061622X/
Moderator Message:
Moved from HYP Practical, shadow left on board. Raptor.
Moved from HYP Practical, shadow left on board. Raptor.